Molenaar, R. ., Radivoyevitch, T. ., Nagata, Y. ., Khurshed, M. ., Przychodzen, B. ., Makishima, H. ., … Maciejewski, J. . (2018). IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-2796 (Original work published 2018)